A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study to Evaluate LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
Latest Information Update: 30 Sep 2024
At a glance
- Drugs CNTX 0290 (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Sponsors Centrexion Therapeutics; Eli Lilly and Company
- 19 Oct 2023 Status changed from not yet recruiting to recruiting.
- 03 Oct 2023 Status changed from planning to not yet recruiting.
- 05 Nov 2020 New trial record